Related Experiment Video
Updated: Jun 11, 2025
Transformation of Probiotic Yeast and Their Recovery from Gastrointestinal Immune Tissues Following Oral Gavage in Mice
Published on: February 8, 2016
Innovative Oral Nano/Gene Delivery System Based on Engineered Modified Saccharomyces cerevisiae for Colorectal Cancer
Tianli Shen1, Xuejun Sun1, Shuanying Yang2
1Department of General Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Abstract:
The efficient delivery of RNA-based drugs to solid tumors remains a formidable obstacle. We aim to develop a safe and efficient oral drug delivery system compatible with RNA-based drugs that is urgently needed to overcome challenges such as enzymatic degradation and gastrointestinal barriers to facilitate effective treatment for treating colorectal cancer (CRC). To address these challenges, we utilized engineered modified Saccharomyces cerevisiae to evaluate the delivery efficacy of miR21-antagomir for treating CRC in preclinical mouse models, including adenomatosis polyposis coli mutant transgenic mice ApcMin/+ and in situ tumor-bearing mice. An orally deliverable gene delivery system, YS@NPs21, was designed. This gene delivery system demonstrated effectively suppressed tumor growth in both ApcMin/+ and in situ tumor-bearing mice models. This system exhibited tumor-targeting capability, effective inhibition of tumor growth, and low toxicity toward nontumor cells. Successful implementation of this innovative oral drug delivery system could offer a straightforward, safe, and RNA drug-compatible approach to CRC treatment, ultimately improving patient outcomes and reducing medical costs.
Insights
Engineered yeast delivers RNA drugs orally to treat colorectal cancer (CRC), effectively suppressing tumor growth with low toxicity. This breakthrough offers a safe and efficient new treatment option.
Area of Science:
- Biotechnology
- Oncology
- Drug Delivery
Background:
- Efficient RNA-based drug delivery to solid tumors, particularly colorectal cancer (CRC), faces significant challenges including enzymatic degradation and gastrointestinal barriers.
- Current delivery methods often struggle to overcome these obstacles, limiting therapeutic efficacy.
Purpose of the Study:
- To develop a safe and efficient oral drug delivery system compatible with RNA-based therapeutics for colorectal cancer (CRC) treatment.
- To evaluate the efficacy of engineered modified *Saccharomyces cerevisiae* for delivering miR21-antagomir in preclinical CRC models.
Main Methods:
- Designed an orally deliverable gene delivery system, YS@NPs21, utilizing engineered modified *Saccharomyces cerevisiae*.
- Evaluated YS@NPs21 in preclinical mouse models of colorectal cancer, including *Apc*Min/+ and in situ tumor-bearing mice.
Main Results:
- The YS@NPs21 system effectively suppressed tumor growth in both *Apc*Min/+ and in situ tumor-bearing mouse models.
- Demonstrated tumor-targeting capability, significant inhibition of tumor growth, and low toxicity toward nontumor cells.
Conclusions:
- The developed oral drug delivery system, YS@NPs21, shows promise as a straightforward, safe, and RNA drug-compatible approach for colorectal cancer (CRC) treatment.
- This innovative system has the potential to improve patient outcomes and reduce healthcare costs associated with CRC therapy.
